StockNow
Calendar
Log in
U.S. Markets

Johnson & Johnson (JNJ) announced that TREMFYA met the primary and major secondary endpoints demonstrating both improvement in axial symptoms and reduction in inflammation by MRI assessment in the Phase 4 STAR study

StockNow breaking-news AI analysis

Johnson & Johnson announced that TREMFYA met primary and major secondary endpoints in the Phase 4 STAR study, showing axial symptom improvements and inflammation reduction via MRI.

1 stocks
JNJJohnson & Johnson$269.82Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

IRGC Spokesperson Mohebbi says "in the event of a new attack, we will use different weapons", YJC reports

Fed

Fed's Williams (Voter) says cannot ignore persistent supply shocks; labour market is not a source of inflationary pressure, adding that tariffs generally do not produce sustained inflation

Politics

US President Trump says very productive meeting with President Xi for both the USA and China